Patents Assigned to Osprey Pharmaceuticals, Ltd.
  • Patent number: 7192736
    Abstract: Nucleic acid moleucles that encode conjugates containing as a ligand a chemokine receptor targeting agent, such as a chemokine, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophils, macrophages, and eosinophils.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: March 20, 2007
    Assignee: Osprey Pharmaceuticals, Ltd.
    Inventors: John R. McDonald, Philip J. Coggins
  • Patent number: 7166702
    Abstract: Conjugates containing as a ligand chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophils, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates can be used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: January 23, 2007
    Assignee: Osprey Pharmaceuticals, Ltd.
    Inventors: John R. McDonald, Philip J. Coggins
  • Patent number: 7157418
    Abstract: Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophiles, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates are used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: January 2, 2007
    Assignee: Osprey Pharmaceuticals, Ltd.
    Inventors: John R. McDonald, Philip J. Coggins